Control of CD44 gene expression for therapeutic use

Details Control of CD44 gene expression for therapeutic use Control of CD44 gene expression for therapeutic use

1995-08-14

1999-11-23

Guzo, David

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

536 231, C07H 2104, C07H 2102

Patent

active

059902990

ABSTRACT:
Neoplastic cells which over-express CD44, including especially non-small cell lung cancer and melanoma cancer cells, are treated with antisense oligonucleotides to control CD44 expression. Test results show that the claimed oligonucleotides significantly decreases cell growth in a CD44 sequence specific manner of lung cancer or melanoma cells, or both, but are largely non-toxic to normal cells. Examples of dosing in a clinical setting are provided.

REFERENCES:
Gura, Science, vol. 278, pp. 1041-1042, Nov. 7, 1997.
Gura, Science, vol. 270, Oct. 27, 1995, pp. 575-577.
Nature Biotechnology, "Antisense '97: A Roundtable on the State of the Industry", vol. 15, Jun. 1997, pp. 519-524.
Sulston et al., Nature, vol. 356, Mar. 5, 1992, pp. 37-41.
Merzak, Abderrahim et al., "CD44 Mediates Human Glioma Cell Adhesion and Invasion in Vitro", Cancer Research, 54, 3988-3992 (Aug. 1, 1994).
Li, Hong et al., "Varian T Cd44 Adhesion Molecules Are Expressed in Human Brain Metastases but Not in Glioblastomas", Cancer Research, 53, 5345-5349 (Nov. 15, 1993).

Affiliated with

Also associated with

Rating

Control of CD44 gene expression for therapeutic use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Control of CD44 gene expression for therapeutic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Control of CD44 gene expression for therapeutic use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1223304